Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Tungming Leung"'
Autor:
Mark Goldin, Kolton Smith, Ioannis Koulas, Tungming Leung, Mayuri Ravi, Sanjit Parhar, Sejal Shah, Kayla Floyd, Lori Ohanesian, Rachel Bain, Daniella Defonte, Kanta Ochani, Amanda Lin, Bhumi Patel, Nikolaos Tsaftaridis, Jack Jnani, Alex C. Spyropoulos
Publikováno v:
TH Open, Vol 08, Iss 02, Pp e209-e215 (2024)
Background Andexanet is U.S. Food and Drug Administration (FDA) approved for the reversal of critical bleeding from factor Xa inhibitors and off-label for surgical reversal. Data are lacking on andexanet administration processes.
Externí odkaz:
https://doaj.org/article/b4c8d7cd0de345d594f879f98c252755
Autor:
Clinton Ehidom, Alfio Carroccio, Vasilieos Bouris, Tungming Leung, Allan M. Conway, Nhan Nguyen, Khalil Qato, Gary Giangola
Publikováno v:
Annals of Vascular Surgery. 72:244-252
Background Endovascular management of isolated profunda femoris artery occlusive disease has not been well studied. Our aim is to analyze the outcomes of endovascular management of profunda artery occlusive disease. Methods This is a retrospective an
Autor:
Martin Lesser, Halis Sonmez, Renee Murray-Bachmann, Marina Krymskaya, Arpita Bhalodkar, Karina Ziskovich, Damian Inlall, Tungming Leung, Leonid Poretsky
Publikováno v:
Endocrine Practice. 26:1331-1336
Objective: The diagnosis of diabetes mellitus is associated with an increased risk of hospital readmissions. The goal of this study was to determine whether there was a difference in the rates of 30-day and 365-day hospital readmissions between diabe
Autor:
Michael Frenkel, Leonid Poretsky, Nyein Chan Swe, Tungming Leung, Minghao Liu, Samihah Ahmed, Aren Skolnick, Karina Ziskovich, Natalie E. Cusano, Eugenia Gianos
Publikováno v:
Endocrine Practice. 27:S75
Autor:
Allan M. Conway, Gary Giangola, Alfio Carroccio, Gautam M. Anand, Tungming Leung, Khalil Qato
Publikováno v:
Journal of Vascular Surgery. 72:e240
Autor:
Meggan Mackay, Tam Quach, Weiqing Huang, Zheng Liu, Martin Lesser, Tungming Leung, Jian Han, Cynthia Aranow, Thomas L. Rothstein, Richard A. Furie, Cosmin Dascalu, Anne Davidson
Publikováno v:
Adaptive Immunity.
Background Belimumab has a therapeutic benefit in active SLE, especially in patients with high titers of anti-dsDNA antibodies. The current study was designed to address whether the profound loss of naive B cells in belimumab treated patients is acco
Autor:
Jian Han, Richard Furie, Weiqing Huang, Zheng Liu, Tam D. Quach, Anne Davidson, Tungming Leung, Qunying Yang, Wenjing Pan, Cosmin Dascalu, Cynthia Aranow, Miranda Byrne-Steele, Thomas L. Rothstein, Meggan Mackay, Martin Lesser
Publikováno v:
JCI insight. 3(17)
Belimumab has therapeutic benefit in active systemic lupus erythematosus (SLE), especially in patients with high-titer anti-dsDNA antibodies. We asked whether the profound B cell loss in belimumab-treated SLE patients is accompanied by shifts in the